PharmacyCodes



Valrubicin [Usan] en es it fr

Valrubicin [Usan] Brand names, Valrubicin [Usan] Analogs

Valrubicin [Usan] Brand Names Mixture

  • No information avaliable

Valrubicin [Usan] Chemical_Formula

C34H36F3NO13

Valrubicin [Usan] RX_link

http://www.rxlist.com/cgi/generic2/rubicin.htm

Valrubicin [Usan] fda sheet

Valrubicin_[Usan] FDA

Valrubicin [Usan] msds (material safety sheet)

Valrubicin [Usan] Synthesis Reference

No information avaliable

Valrubicin [Usan] Molecular Weight

723.644 g/mol

Valrubicin [Usan] Melting Point

116-117oC

Valrubicin [Usan] H2O Solubility

insoluble

Valrubicin [Usan] State

Solid

Valrubicin [Usan] LogP

3.332

Valrubicin [Usan] Dosage Forms

Liquid

Valrubicin [Usan] Indication

Bladder cancer

Valrubicin [Usan] Pharmacology

When 800 mg Valstar was administered intravesically to patients with carcinoma in situ, Valstar penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytoxicity to human bladder cells cultured in vitro. During the two-hour dose-retention period, the metabolism of Valstar to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol was neglible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of Valstar, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of Valstar were absorbed into the plasma.

Valrubicin [Usan] Absorption

No information avaliable

Valrubicin [Usan] side effects and Toxicity

No information avaliable

Valrubicin [Usan] Patient Information

Valrubicin [Usan] Organisms Affected

Humans and other mammals